Intensive insulin therapy in septic shock

Area of Science:

• Critical Care Medicine
• Endocrinology
• Metabolic Disorders

Background:

• The Surviving Sepsis guidelines recommend intensive insulin therapy (IIT) to maintain blood glucose below 8.3 mmol/L in severe sepsis.
• Recent trials and post-hoc analyses suggest potential benefits of IIT in critically ill patients, necessitating careful examination.

Purpose of the Study:

• To review the molecular and metabolic mechanisms underlying the potential benefits of IIT in severe sepsis.
• To evaluate the evidence supporting IIT's efficacy in patients with severe sepsis.
• To assess the risks of hypoglycemia associated with IIT implementation.

Main Methods:

• Review of recent clinical trials and post-hoc analyses concerning intensive insulin therapy in critically ill patients.
• Examination of molecular and metabolic pathways affected by insulin therapy.
• Analysis of reported outcomes, including morbidity, mortality, and hypoglycemia rates.

Main Results:

• Patients with severe sepsis may benefit from IIT due to its metabolic effects and the prolonged intensive care unit (ICU) stays.
• Evidence suggests a positive impact of IIT on patient outcomes, although risks like hypoglycemia require careful management.
• The benefits of IIT are linked to achieving the lowest safely attainable glycemic range.

Conclusions:

• Intensive insulin therapy is likely beneficial for patients with severe sepsis.
• Implementation of IIT should aim for the lowest safe glycemic range, actively mitigating hypoglycemia risks.
• Further research may refine optimal glycemic targets and management strategies for IIT in severe sepsis.